An update on breast cancer prevention trials

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 2, 2006, Pages 498-501

  Wickerham, D L ^a   Fourchotte, V ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

Breast cancer prevention; Cancer prevention trial; Clinical trials

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; ENDOMETRIUM CANCER; FOLLOW UP; HUMAN; LUNG EMBOLISM; OSTEOPOROSIS; PRIORITY JOURNAL; STROKE; UNSPECIFIED SIDE EFFECT;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FEMALE; HUMANS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33748790908     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00679.x     Document Type: Conference Paper

References (18)

1. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005;97:1652-62.
3. IBIS Investigators Writing Committee. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002;360:817-24.
4. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7.
5. Veronesi U, Maisonneuve P, Sacchini V et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-24.
6. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003;361:296-300.
7. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-97.
8. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67.
9. Bonneterre J, Buzdar A, Nabholtz JM et al. Arimidex Writing Committee. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
10. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
11. Dirix L, Piccart MJ, Lohrisch C et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organization for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn [abstract]. Proc Am Soc Clin Oncol 2001;20:29a. Abstract 114.
12. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;11:1527-32.
13. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94.
14. Thüerlimann B. Adjuvant hormonal therapy for breast cancer: an evolving process (archived web conference). Paper presented at: Primary Therapy of Early Breast Cancer 9th International Conference; January 26-29, 2005; St. Gallen, Switzerland. Available at: www.medscape.com/viewprogram/3800_pnt. Accessed March 3, 2005.
15. Jakesz R, on behalf of the ABCSG and the GABG. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,224 women enrolled in the ABCSG Trial 8 and the ARNO 95 trial. Paper presented at: 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX.
16. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
17. Coombes RC, Hall E, Gibson LJ et al., for the Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
18. Baum M, Budzar AU., Cuzick et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.